The most common therapeutic regimens for these conditions are either alone or combinations of Fludarabine, Nab-Paclitaxel, and cyclophosphamide, which has shown promising anti-tumor efficacy while exhibiting no events of grade-3 neurotoxicity or CRS (104, 206, 207, 270–272), except for one case (6%) of grade-3 CRS in a study assessing the combination of EGFR-specific CAR T-cell with Nab-Paclitaxel and cyclophosphamide in 17 patients with stage 4 biliary tract cancers (273). This evidence concerns the gene EGFR and biliary tract neoplasm.